The high p53 expression detected in CMT-622 suggests dysregulated tumor-suppressive signaling, providing a valuable platform to investigate p53-mediated pathways in CMT pathogenesis and to evaluate its potential as a therapeutic target. The gene discussed is TP53; the disease is Charcot-Marie-Tooth disease.